November 26, 2025

Market Outlook and Forecast

Global Asthma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) – 2025 To 2035

Thelansis’s “Global Asthma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) – 2025 To 2035″ covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential ⁠⁠Asthma treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

November 21, 2025

Market Outlook and Forecast

Global ⁠Brain Metastasis (BM) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) – 2025 To 2035

Thelansis’s “Global ⁠Brain Metastasis (BM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) – 2025 To 2035″ covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential ⁠⁠Brain Metastasis treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

November 24, 2025

Market Outlook and Forecast

Herpetic Keratitis (HK) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035

Thelansis’s “Herpetic Keratitis (HK) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Herpetic Keratitis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

November 28, 2025

Market Outlook and Forecast

Familial Adenomatous Polyposis (FAP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035

Thelansis’s “Familial Adenomatous Polyposis (FAP) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Familial Adenomatous Polyposis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

November 25, 2025

Market Outlook and Forecast

Microvillus Inclusion Disease (MVID) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035

Thelansis’s “Microvillus Inclusion Disease (MVID) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Microvillus Inclusion Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

November 24, 2025

Market Outlook and Forecast

Metastatic Cutaneous Melanoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035

Thelansis’s “Metastatic Cutaneous Melanoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Metastatic Cutaneous Melanoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

November 19, 2025

Market Outlook and Forecast

Relapsed or Refractory Waldenstrom Macroglobulinemia (r/r WM) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035

Thelansis’s “Relapsed or Refractory Waldenstrom Macroglobulinemia (r/r WM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Relapsed or Refractory Waldenstrom Macroglobulinemia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

November 26, 2025

Market Outlook and Forecast

Steroid-Refractory Graft-Versus-Host Disease (SR-GVHD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035

Thelansis’s “Steroid-Refractory Graft-Versus-Host Disease (SR-GVHD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Steroid-Refractory Graft-Versus-Host Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

November 24, 2025

Market Outlook and Forecast

Advanced or Metastatic ER+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035

Thelansis’s “Advanced or Metastatic ER+/HER2- Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced or Metastatic ER+/HER2- Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

November 27, 2025

Market Outlook and Forecast

McCune-Albright Syndrome (MAS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035

Thelansis’s “McCune-Albright Syndrome (MAS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential McCune-Albright Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

November 25, 2025

Market Outlook and Forecast

Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035

Thelansis’s “Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Steroid-Refractory Acute Graft-Versus-Host Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

January 8, 2026

Market Outlook and Forecast

Polycythemia Vera (PV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036

Thelansis’s “Polycythemia Vera (PV) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Polycythemia Vera treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

1 2 144